Dr. Marshall R. Posner, MD

Dr. Posner practices at Cancer Center of South Florida in Palm Springs, Florida.

Dr. Posner's NPI, 1700847753, was assigned on March 29, 2006. Dr. Posner graduated from Tufts University School Of Medicine in 1975. Dr. Posner holds New York license 258260.

Dr. Posner's primary practice is Cancer Center of South Florida, at 1630 S Congress Ave, Palm Springs, FL 33461 in Palm Beach County. The practice phone is (561) 253-3980.

Dr. Posner's primary practice is Cancer Center of South Florida in Palm Springs, Florida. Dr. Posner is also affiliated with Jupiter Medical Center. The medical group on file is Tampa General Hospital Cancer Center of South Florida. Dmand AI also links Dr. Posner to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Posner practices. Vendor and product names are available with a free account.

Medical oncology is Dr. Posner's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Posner is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Posner's licenses on file in 4 states: New York, Florida, Massachusetts and Rhode Island.

Dmand AI lists breast cancer and prostate cancer among the conditions Dr. Posner treats.

CMS data shows 152 Medicare services from Dr. Posner across 3 procedure codes in 2024, for 80 Medicare patients. Medicare paid $17,247 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 80 Medicare patients who saw Dr. Posner in 2024. The largest group is 75 to 84, with 32 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 26% are also on Medicaid. Their average risk score is 2.76, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Posner's median patient age at 56, with 50% women.

In 2024, Dr. Posner wrote 151 Medicare Part D claims for 30 patients. 84% of them were for generic drugs. CMS names the drug for 87 of them, across 2 drugs with 11 or more claims each, at $749 in total drug cost. In 2023, CMS named 68 claims across 1 drug.

Dr. Posner accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Posner as offering telehealth.

Dmand AI links 288 papers to Dr. Posner, published from 2005 to 2025. 2017 was the busiest year, with 7. The most frequent topics are Head and Neck Neoplasms, Carcinoma, Squamous Cell and Antineoplastic Combined Chemotherapy Protocols. Dr. Posner has published most often in Cancer. Dr. Posner's most frequent co-authors are Eric M. Genden, MD, Richard L. Bakst, MD and Vishal Gupta, MD.

Dmand AI links Dr. Posner to 15 clinical trials, 6 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell and Neoplasms, Squamous Cell. Dana-Farber Cancer Institute sponsors the most, 7.

CMS Open Payments shows 88 general payments to Dr. Posner from 5 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 92% of the total. Merck Sharp & Dohme Corporation paid the most, $120,556.

Dmand AI lists 6 awards for Dr. Posner, most recently America's Top Doctors in 2014.

Dr. Posner graduated from Tufts University School Of Medicine in 1975.

Dr. Posner is in network with 11 carriers, including Excellus BlueCross BlueShield, Blue Cross Blue Shield of Michigan and Elevance. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.